Sohail T Ali,Anne E Gill,Ann Lewendon
Sohail T Ali
The urgent need for new antibiotics has led to an explosion in the number and diversity of antibiotic drug targets under investigation. The majority of such targets are enzymes required for essential cellular functions. Often, such novel ta...
Oludotun A Phillips,Wandikayi C Matowe
Oludotun A Phillips
A total of 48 patents dealing with disclosures on the different classes of antibacterial agents, including the beta-lactams, oxazolidinones, macrolides, quinolones, tetracyclines and miscellaneous antibacterial agents reported between Janua...
David M Vigushin
David M Vigushin
The depsipeptide FR-901228 is a histone deacetylas inhibitor under development by Fujisawa and the National Cancer Institute as a potential treatment for neoplasm. By May 2002, phase II trials had commenced in the US [452248], [461017].
Tracy E Kim,John R Murren
Tracy E Kim
Erlotinib (CP-358774, OSI-774, Tarceva), a quinazoline derivative, is an orally active epidermal growth factor receptor tyrosine kinase inhibitor under development jointly by Genentech, OSI (formerly Oncogene Science) and Roche, both as mon...
Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy [0.03%]
肿瘤性缺血的选择性诱导：抗癌药物的血管靶向剂的发展
David J Chaplin,Sally A Hill
David J Chaplin
Frovatriptan Vernalis [0.03%]
弗罗瓦曲坦维尔纳里斯公司
Hermann A M Mucke
Hermann A M Mucke
Vanguard (now Vernalis) has developed frovatriptan, a selective 5-HT1B/1D partial agonist licensed from GlaxoSmithKline as a potential treatment for migraine [188478], [194382], [377863].
Avinza Elan [0.03%]
爱文扎艾兰
Marilyn R Semenchuk
Marilyn R Semenchuk
Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multipartic...
Eletriptan Pfizer [0.03%]
埃来西坦 Pfizer公司製品
Paul J L M Strijbos,Andrew A Parsons,Anders Fugelli
Paul J L M Strijbos
Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity...
Werner Kiefer,Gerd Dannhardt
Werner Kiefer
The discovery of the two isoenzymes of cyclooxygenase COX-1 and COX-2 and their separate functions, localization and regulation, has initiated the search for new and more selective inhibitors of prostaglandin biosynthesis. Selective COX-2 i...
David Borsook,Alexander Ploghaus,Lino Becerra
David Borsook
Analgesia is defined as loss of pain sensation without loss of consciousness; pain may be acute or chronic. Acute pain is well understood and can be controlled with currently available analgesics. Chronic pain, however, is not effectively c...